Viewing StudyNCT00141531



Ignite Creation Date: 2024-05-05 @ 11:48 AM
Last Modification Date: 2024-10-26 @ 9:14 AM
Study NCT ID: NCT00141531
Status: COMPLETED
Last Update Posted: 2012-06-14
First Post: 2005-08-30

Brief Title: Phase II Trial of EOquin in High-risk Superficial Bladder Cancer
Sponsor: Spectrum Pharmaceuticals Inc
Organization: Spectrum Pharmaceuticals Inc

Key Dates - Follows AllAPIJSON File Order

Start Date: 2005-07
Start Date Type: None
Primary Completion Date: 2009-12
Primary Completion Date Type: ACTUAL
Completion Date: 2009-12
Completion Date Type: ACTUAL
First Submit Date: 2005-08-30
First Submit QC Date: August 30 2005
Study First Post Date: 2005-09-01
Study First Post Date Type: ESTIMATED
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: None
Results First Post Date Type: None
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2012-06-13
Last Update Post Date: 2012-06-14
Last Update Post Date Type: ESTIMATED